公開日期 | 題名 | 作者 | 關聯 | scopus | WOS | 全文 |
2019 | Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. | Bavli, Y; Winkler, I; Chen, BM; Roffler, S ; Cohen, R; Szebeni, J; Barenholz, Y | Journal of controlled release : official journal of the Controlled Release Society 306, 138-148 | | | |
2020 | PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies. | Bavli, Y; Chen, BM; Roffler, SR ; Dobrovolskaia, MA; Elnekave, E; Ash, S; Barenholz, Y; Turjeman, K | Molecules (Basel, Switzerland) 25(3), 558 | | | |
2020 | Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin via Formation of the Membrane Attack Complex | Chen, E; Chen, BM; Su, YC; Chang, YC ; Cheng, TL; Barenholz, Y; Roffler, SR | ACS nano 14(7), 7808-7822 | | | |